Search

Your search keyword '"Thaçi, Diamant"' showing total 7 results
Start Over Author "Thaçi, Diamant" Journal american journal of clinical dermatology
7 results on '"Thaçi, Diamant"'

1. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)

Author

Silverberg, Jonathan I., Gooderham, Melinda J., Paller, Amy S., Deleuran, Mette, Bunick, Christopher G., Gold, Linda F. Stein, Hijnen, DirkJan, Calimlim, Brian M., Lee, Wan-Ju, Teixeira, Henrique D., Hu, Xiaofei, Zhang, Shiyu, Yang, Yang, Grada, Ayman, Platt, Andrew M., and Thaçi, Diamant

Published
2024
Full Text
View/download PDF

4. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

Author

Eichenfield, Lawrence F, Bieber, Thomas, Beck, Lisa A, Simpson, Eric L, Thaçi, Diamant, de Bruin-Weller, Marjolein, Deleuran, Mette, Silverberg, Jonathan I, Ferrandiz, Carlos, Fölster-Holst, Regina, Chen, Zhen, Graham, Neil MH, Pirozzi, Gianluca, Akinlade, Bolanle, Yancopoulos, George D, and Ardeleanu, Marius

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Clinical Trials and Supportive Activities, Clinical Research, Patient Safety, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Skin, Inflammatory and immune system, Infection, Good Health and Well Being, Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Dermatitis, Atopic, Double-Blind Method, Humans, Incidence, Injections, Subcutaneous, Placebos, Randomized Controlled Trials as Topic, Severity of Illness Index, Skin Diseases, Infectious, Treatment Outcome, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundPatients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma.ObjectiveThe aim was to determine the impact of dupilumab on infection rates in patients with moderate-to-severe AD.MethodsThis analysis pooled data from seven randomized, placebo-controlled dupilumab trials in adults with moderate-to-severe AD. Exposure-adjusted analyses assessed infection rates.ResultsOf 2932 patients, 1091 received placebo, 1095 dupilumab 300 mg weekly, and 746 dupilumab 300 mg every 2 weeks. Treatment groups had similar infection rates overall per 100 patient-years (placebo, 155; dupilumab weekly, 150; dupilumab every 2 weeks, 156; dupilumab combined, 152), and similar non-skin infection rates. Serious/severe infections were reduced with dupilumab (risk ratio 0.43; p

Published
2019

6. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

Author

Beck, Lisa A., Thaçi, Diamant, Deleuran, Mette, Blauvelt, Andrew, Bissonnette, Robert, de Bruin-Weller, Marjolein, Hide, Michihiro, Sher, Lawrence, Hussain, Iftikhar, Chen, Zhen, Khokhar, Faisal A., Beazley, Bethany, Ruddy, Marcella, Patel, Naimish, Graham, Neil M. H., Ardeleanu, Marius, and Shumel, Brad

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results